metformin has been researched along with Bone Cancer in 21 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Thus, we hypothesized that the addition of metformin to everolimus and exemestane, could lead to better outcomes in overweight and obese patients with metastatic, hormone receptor-positive, HER2-negative breast cancer." | 9.30 | Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. ( Chavez Mac Gregor, M; Esteva, FJ; Griner, RL; Hess, KR; Hodge, S; Hortobagyi, GN; Koenig, KH; Moulder, SL; Patel, MM; Raghavendra, AS; Shroff, GS; Ueno, NT; Valero, V; Yam, C; Yeung, SJ, 2019) |
| "The effect of metformin on primary bone cancer risk has not been researched." | 8.02 | Metformin and primary bone cancer risk in Taiwanese patients with type 2 diabetes mellitus. ( Tseng, CH, 2021) |
| "This preclinical study suggests that Metformin may be a potentially useful therapeutic agent and chemosensitizer of osteosarcoma stem-like cells to doxorubicin." | 7.88 | Therapeutic potential of the metabolic modulator Metformin on osteosarcoma cancer stem-like cells. ( Abrunhosa, AJ; Fontes-Ribeiro, C; Gomes, CMF; Martins-Neves, SR; Paiva-Oliveira, DI, 2018) |
| "Metformin can enhance cancer cell chemosensitivity to anticancer drugs." | 5.91 | Metformin sensitises osteosarcoma to chemotherapy via the IGF-1R/miR-610/FEN1 pathway. ( Dong, S; Kang, J; Li, Z; Ma, X; Peng, Z; Wang, J; Wang, Y; Xiao, Y; Zhu, Z, 2023) |
| "Metformin has long been an attractive therapeutic option for EwS, but hypoxia limits its efficacy." | 5.56 | Imatinib revives the therapeutic potential of metformin on ewing sarcoma by attenuating tumor hypoxic response and inhibiting convergent signaling pathways. ( Cheng, H; Lau, CC; Nan, X; Qiu, B; Sheng, J; Wang, J; Wong, STC; Yin, Z; Yustein, JT; Zhao, H, 2020) |
| "Osteosarcoma is the most frequently diagnosed primary malignant bone sarcoma in children and adolescents." | 5.51 | Metformin Suppresses Self-Renewal Ability and Tumorigenicity of Osteosarcoma Stem Cells via Reactive Oxygen Species-Mediated Apoptosis and Autophagy. ( Che, J; Luo, J; Peng, S; Shang, P; Wang, F; Wang, Y; Zhang, G; Zhao, B; Zhou, L, 2019) |
| "Metformin treatment of osteosarcoma cells enhanced the effects of chemotherapy via suppression of N-cadherin." | 5.46 | Metformin reduces SATB2-mediated osteosarcoma stem cell-like phenotype and tumor growth via inhibition of N-cadherin/NF-kB signaling. ( Fang, W; Huang, ZW; Kang, Y; Lu, JC; Shen, JN; Song, GH; Tang, QL; Wang, J; Wang, YQ; Xu, HY; Yang, HL; Zhu, XJ; Zou, CY, 2017) |
| "Osteosarcoma is the most common type of primary bone tumor, novel therapeutic agents for which are urgently needed." | 5.46 | Simvastatin-Induced Apoptosis in Osteosarcoma Cells: A Key Role of RhoA-AMPK/p38 MAPK Signaling in Antitumor Activity. ( Fukuchi, Y; Kamel, WA; Maki, K; Matsuo, K; Muto, A; Nobusue, H; Onishi, N; Saya, H; Shimizu, T; Sugihara, E; Yamaguchi-Iwai, S, 2017) |
| " Thus, we hypothesized that the addition of metformin to everolimus and exemestane, could lead to better outcomes in overweight and obese patients with metastatic, hormone receptor-positive, HER2-negative breast cancer." | 5.30 | Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. ( Chavez Mac Gregor, M; Esteva, FJ; Griner, RL; Hess, KR; Hodge, S; Hortobagyi, GN; Koenig, KH; Moulder, SL; Patel, MM; Raghavendra, AS; Shroff, GS; Ueno, NT; Valero, V; Yam, C; Yeung, SJ, 2019) |
| "The effect of metformin on primary bone cancer risk has not been researched." | 4.02 | Metformin and primary bone cancer risk in Taiwanese patients with type 2 diabetes mellitus. ( Tseng, CH, 2021) |
| "This preclinical study suggests that Metformin may be a potentially useful therapeutic agent and chemosensitizer of osteosarcoma stem-like cells to doxorubicin." | 3.88 | Therapeutic potential of the metabolic modulator Metformin on osteosarcoma cancer stem-like cells. ( Abrunhosa, AJ; Fontes-Ribeiro, C; Gomes, CMF; Martins-Neves, SR; Paiva-Oliveira, DI, 2018) |
| " Ten chondrosarcoma cell lines were treated with the metabolic compounds CB-849, metformin, phenformin (lipophilic analogue of metformin) and chloroquine." | 3.88 | Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation. ( Addie, RD; Bovée, JVMG; Cleton-Jansen, AM; Cleven, AHG; de Jong, Y; Kruisselbrink, AB; Molenaar, RJ; Niessen, B; Peterse, EFP; van den Akker, BEWM, 2018) |
| "Metformin can enhance cancer cell chemosensitivity to anticancer drugs." | 1.91 | Metformin sensitises osteosarcoma to chemotherapy via the IGF-1R/miR-610/FEN1 pathway. ( Dong, S; Kang, J; Li, Z; Ma, X; Peng, Z; Wang, J; Wang, Y; Xiao, Y; Zhu, Z, 2023) |
| "Metformin has long been an attractive therapeutic option for EwS, but hypoxia limits its efficacy." | 1.56 | Imatinib revives the therapeutic potential of metformin on ewing sarcoma by attenuating tumor hypoxic response and inhibiting convergent signaling pathways. ( Cheng, H; Lau, CC; Nan, X; Qiu, B; Sheng, J; Wang, J; Wong, STC; Yin, Z; Yustein, JT; Zhao, H, 2020) |
| "Osteosarcoma is the most frequently diagnosed primary malignant bone sarcoma in children and adolescents." | 1.51 | Metformin Suppresses Self-Renewal Ability and Tumorigenicity of Osteosarcoma Stem Cells via Reactive Oxygen Species-Mediated Apoptosis and Autophagy. ( Che, J; Luo, J; Peng, S; Shang, P; Wang, F; Wang, Y; Zhang, G; Zhao, B; Zhou, L, 2019) |
| "Osteosarcoma is an aggressive bone tumor characterized by biological and molecular heterogeneity, possibly dependent on CSCs." | 1.48 | In vitro and in vivo characterization of stem-like cells from canine osteosarcoma and assessment of drug sensitivity. ( Bajetto, A; Barbieri, F; Campanella, C; Corsaro, A; Daga, A; De Maria, R; Ferrari, A; Florio, T; Gatti, M; Maniscalco, L; Pattarozzi, A; Ratto, A; Solari, A; Thellung, S; Würth, R, 2018) |
| "Metformin treatment of osteosarcoma cells enhanced the effects of chemotherapy via suppression of N-cadherin." | 1.46 | Metformin reduces SATB2-mediated osteosarcoma stem cell-like phenotype and tumor growth via inhibition of N-cadherin/NF-kB signaling. ( Fang, W; Huang, ZW; Kang, Y; Lu, JC; Shen, JN; Song, GH; Tang, QL; Wang, J; Wang, YQ; Xu, HY; Yang, HL; Zhu, XJ; Zou, CY, 2017) |
| "Osteosarcoma is the most common type of primary bone tumor, novel therapeutic agents for which are urgently needed." | 1.46 | Simvastatin-Induced Apoptosis in Osteosarcoma Cells: A Key Role of RhoA-AMPK/p38 MAPK Signaling in Antitumor Activity. ( Fukuchi, Y; Kamel, WA; Maki, K; Matsuo, K; Muto, A; Nobusue, H; Onishi, N; Saya, H; Shimizu, T; Sugihara, E; Yamaguchi-Iwai, S, 2017) |
| "Metformin-treatment of osteoblastic cells prevented these AGE-induced alterations." | 1.35 | Metformin reverts deleterious effects of advanced glycation end-products (AGEs) on osteoblastic cells. ( Arnol, V; Bruzzone, L; Cortizo, AM; Gangoiti, MV; McCarthy, AD; Schurman, L; Sedlinsky, C, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (4.76) | 29.6817 |
| 2010's | 15 (71.43) | 24.3611 |
| 2020's | 5 (23.81) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, S | 1 |
| Xiao, Y | 1 |
| Zhu, Z | 1 |
| Ma, X | 1 |
| Peng, Z | 1 |
| Kang, J | 1 |
| Wang, J | 4 |
| Wang, Y | 2 |
| Li, Z | 1 |
| Huang, S | 1 |
| Ren, L | 1 |
| Beck, JA | 1 |
| Phelps, TE | 1 |
| Olkowski, C | 1 |
| Ton, A | 1 |
| Roy, J | 1 |
| White, ME | 1 |
| Adler, S | 1 |
| Wong, K | 1 |
| Cherukuri, A | 1 |
| Zhang, X | 1 |
| Basuli, F | 1 |
| Choyke, PL | 1 |
| Jagoda, EM | 1 |
| LeBlanc, AK | 1 |
| Nan, X | 1 |
| Cheng, H | 1 |
| Yin, Z | 1 |
| Sheng, J | 1 |
| Qiu, B | 1 |
| Lau, CC | 1 |
| Yustein, JT | 1 |
| Zhao, H | 1 |
| Wong, STC | 1 |
| Zhao, B | 1 |
| Luo, J | 1 |
| Zhou, L | 1 |
| Che, J | 1 |
| Wang, F | 1 |
| Peng, S | 1 |
| Zhang, G | 1 |
| Shang, P | 1 |
| Tan, W | 1 |
| Gao, C | 1 |
| Feng, P | 1 |
| Liu, Q | 1 |
| Liu, C | 1 |
| Wang, Z | 1 |
| Deng, Y | 1 |
| Shuai, C | 1 |
| Tseng, CH | 1 |
| Paiva-Oliveira, DI | 1 |
| Martins-Neves, SR | 1 |
| Abrunhosa, AJ | 1 |
| Fontes-Ribeiro, C | 1 |
| Gomes, CMF | 1 |
| Xu, HY | 1 |
| Fang, W | 1 |
| Huang, ZW | 1 |
| Lu, JC | 1 |
| Wang, YQ | 1 |
| Tang, QL | 1 |
| Song, GH | 1 |
| Kang, Y | 1 |
| Zhu, XJ | 1 |
| Zou, CY | 1 |
| Yang, HL | 1 |
| Shen, JN | 1 |
| Gatti, M | 1 |
| Solari, A | 1 |
| Pattarozzi, A | 1 |
| Campanella, C | 1 |
| Thellung, S | 1 |
| Maniscalco, L | 1 |
| De Maria, R | 1 |
| Würth, R | 1 |
| Corsaro, A | 1 |
| Bajetto, A | 1 |
| Ratto, A | 1 |
| Ferrari, A | 1 |
| Daga, A | 1 |
| Barbieri, F | 1 |
| Florio, T | 1 |
| Peterse, EFP | 1 |
| Niessen, B | 1 |
| Addie, RD | 1 |
| de Jong, Y | 1 |
| Cleven, AHG | 1 |
| Kruisselbrink, AB | 1 |
| van den Akker, BEWM | 1 |
| Molenaar, RJ | 1 |
| Cleton-Jansen, AM | 1 |
| Bovée, JVMG | 1 |
| Yam, C | 1 |
| Esteva, FJ | 1 |
| Patel, MM | 1 |
| Raghavendra, AS | 1 |
| Ueno, NT | 1 |
| Moulder, SL | 1 |
| Hess, KR | 1 |
| Shroff, GS | 1 |
| Hodge, S | 1 |
| Koenig, KH | 1 |
| Chavez Mac Gregor, M | 1 |
| Griner, RL | 1 |
| Yeung, SJ | 1 |
| Hortobagyi, GN | 1 |
| Valero, V | 1 |
| Duo, J | 1 |
| Ma, Y | 1 |
| Wang, G | 2 |
| Han, X | 1 |
| Zhang, C | 1 |
| Chen, TY | 1 |
| Qin, S | 1 |
| Duan, Y | 1 |
| Quattrini, I | 1 |
| Conti, A | 1 |
| Pazzaglia, L | 1 |
| Novello, C | 1 |
| Ferrari, S | 1 |
| Picci, P | 2 |
| Benassi, MS | 1 |
| Garofalo, C | 1 |
| Capristo, M | 1 |
| Manara, MC | 1 |
| Mancarella, C | 1 |
| Landuzzi, L | 1 |
| Belfiore, A | 1 |
| Lollini, PL | 1 |
| Scotlandi, K | 1 |
| Issaq, SH | 1 |
| Teicher, BA | 1 |
| Monks, A | 1 |
| Babcook, MA | 1 |
| Shukla, S | 1 |
| Fu, P | 1 |
| Vazquez, EJ | 1 |
| Puchowicz, MA | 1 |
| Molter, JP | 1 |
| Oak, CZ | 1 |
| MacLennan, GT | 1 |
| Flask, CA | 1 |
| Lindner, DJ | 1 |
| Parker, Y | 1 |
| Daneshgari, F | 1 |
| Gupta, S | 1 |
| Tandon, M | 1 |
| Chen, Z | 1 |
| Othman, AH | 1 |
| Pratap, J | 1 |
| Kamel, WA | 1 |
| Sugihara, E | 1 |
| Nobusue, H | 1 |
| Yamaguchi-Iwai, S | 1 |
| Onishi, N | 1 |
| Maki, K | 1 |
| Fukuchi, Y | 1 |
| Matsuo, K | 1 |
| Muto, A | 1 |
| Saya, H | 1 |
| Shimizu, T | 1 |
| Nilsson, S | 1 |
| Huelsenbeck, J | 1 |
| Fritz, G | 1 |
| Schurman, L | 1 |
| McCarthy, AD | 1 |
| Sedlinsky, C | 1 |
| Gangoiti, MV | 1 |
| Arnol, V | 1 |
| Bruzzone, L | 1 |
| Cortizo, AM | 1 |
1 trial available for metformin and Bone Cancer
| Article | Year |
|---|---|
Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast | 2019 |
20 other studies available for metformin and Bone Cancer
| Article | Year |
|---|---|
Metformin sensitises osteosarcoma to chemotherapy via the IGF-1R/miR-610/FEN1 pathway.
Topics: Animals; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cytotoxins; Flap Endonucleases; Human | 2023 |
Exploration of Imaging Biomarkers for Metabolically-Targeted Osteosarcoma Therapy in a Murine Xenograft Model.
Topics: Animals; Biomarkers; Bone Neoplasms; Child; Disease Models, Animal; Fluorodeoxyglucose F18; Heterogr | 2023 |
Imatinib revives the therapeutic potential of metformin on ewing sarcoma by attenuating tumor hypoxic response and inhibiting convergent signaling pathways.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Breast Neoplasms | 2020 |
Metformin Suppresses Self-Renewal Ability and Tumorigenicity of Osteosarcoma Stem Cells via Reactive Oxygen Species-Mediated Apoptosis and Autophagy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Bone Neoplasms; Cell Cycle; Cell Proliferation | 2019 |
Dual-functional scaffolds of poly(L-lactic acid)/nanohydroxyapatite encapsulated with metformin: Simultaneous enhancement of bone repair and bone tumor inhibition.
Topics: Bone Neoplasms; Durapatite; Humans; Lactic Acid; Metformin; Osteogenesis; Polyesters; Tissue Enginee | 2021 |
Metformin and primary bone cancer risk in Taiwanese patients with type 2 diabetes mellitus.
Topics: Bone Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incidence; Male; Metformin; | 2021 |
Therapeutic potential of the metabolic modulator Metformin on osteosarcoma cancer stem-like cells.
Topics: Adenylate Kinase; Adolescent; Antibiotics, Antineoplastic; Bone Neoplasms; Cell Line, Tumor; Cell Pr | 2018 |
Metformin reduces SATB2-mediated osteosarcoma stem cell-like phenotype and tumor growth via inhibition of N-cadherin/NF-kB signaling.
Topics: Adolescent; Animals; Bone Neoplasms; Cadherins; Cell Proliferation; Female; Humans; Male; Matrix Att | 2017 |
In vitro and in vivo characterization of stem-like cells from canine osteosarcoma and assessment of drug sensitivity.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Pr | 2018 |
Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation.
Topics: Antineoplastic Agents; Benzeneacetamides; Bone Neoplasms; Chloroquine; Chondrosarcoma; Drug Screenin | 2018 |
Metformin synergistically enhances antitumor activity of histone deacetylase inhibitor trichostatin a against osteosarcoma cell line.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Apoptosis; Blotting, Western; Bone Neoplasms; Cell Cy | 2013 |
Inhibitory effect of metformin on bone metastasis of cancer via OPG/RANKL/RANK system.
Topics: Bone Neoplasms; Diabetes Complications; Gene Expression Regulation, Neoplastic; Humans; Metformin; M | 2013 |
Metformin inhibits growth and sensitizes osteosarcoma cell lines to cisplatin through cell cycle modulation.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2014 |
Metformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drug.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2013 |
Bioenergetic properties of human sarcoma cells help define sensitivity to metabolic inhibitors.
Topics: Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Respiration; Deoxyglucose; Electron Trans | 2014 |
Synergistic simvastatin and metformin combination chemotherapy for osseous metastatic castration-resistant prostate cancer.
Topics: Animals; Anticholesteremic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; C | 2014 |
Role of Runx2 in IGF-1Rβ/Akt- and AMPK/Erk-dependent growth, survival and sensitivity towards metformin in breast cancer bone metastasis.
Topics: AMP-Activated Protein Kinases; Aniline Compounds; Animals; Benzamides; Bone Neoplasms; Breast Neopla | 2016 |
Simvastatin-Induced Apoptosis in Osteosarcoma Cells: A Key Role of RhoA-AMPK/p38 MAPK Signaling in Antitumor Activity.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Movement; | 2017 |
Mevalonate pathway inhibitors affect anticancer drug-induced cell death and DNA damage response of human sarcoma cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Bone Neoplasms; Cell Cycle; Cell Proliferation; | 2011 |
Metformin reverts deleterious effects of advanced glycation end-products (AGEs) on osteoblastic cells.
Topics: Animals; Bone Neoplasms; Cell Differentiation; Cell Line; Cell Line, Tumor; Cells, Cultured; Glycati | 2008 |